Newer aspects in the diagnosis, treatment, and prevention of non-small cell lung cancer. Part II.
Langer
C J
CJ
Department of Medical Oncology Fox Chase Cancer Center, Philadelphia, Pennsvlvania, USA.
Rosvold
E
E
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000235:genetics / Q000517:prevention & control / Q000628:therapy*; D018890:Chemoprevention / Q000191:economics; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D019008:Drug Resistance, Neoplasm; D016147:Genes, Tumor Suppressor / Q000235:genetics; D020022:Genetic Predisposition to Disease; D006133:Growth Substances / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000517:prevention & control / Q000628:therapy*; D009857:Oncogenes / Q000235:genetics; D017239:Paclitaxel / Q000627:therapeutic use; D011379:Prognosis; D011788:Quality of Life; D059004:Topoisomerase I Inhibitors
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D006133:Growth Substances; D059004:Topoisomerase I Inhibitors; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin